Febuxostat 40 mg is a potent, selective xanthine oxidase inhibitor formulated for the effective management and prevention of gout and hyperuricemia. Gout occurs when excess uric acid forms crystals around the joints, causing intense pain, inflammation, and swelling. Febuxostat lowers uric acid levels by blocking xanthine oxidase, the enzyme responsible for uric acid production, helping prevent gout flare-ups and long-term joint complications. UXOBUS-40 delivers reliable uric acid control with once-daily dosing, making it a preferred therapy for chronic gout management and maintaining stable serum urate levels in at-risk individuals.
Febuxostat (40 mg): A selective, non-purine xanthine oxidase inhibitor that reduces uric acid formation, helping prevent crystal deposition and gout attacks.
Potent Uric Acid Reduction: Effectively lowers serum urate levels to prevent painful gout flares.
Selective XO Inhibition: Targets the primary metabolic pathway responsible for uric acid production.
Prevents Gout Progression: Helps avoid complications like joint damage, tophi formation, and recurrent inflammation.
Once-Daily Dosing: Simple regimen improves adherence and long-term control.
Suitable for Long-Term Use: Designed to maintain stable uric acid levels over extended therapy periods.
May include mild skin rash, liver enzyme elevation, nausea, joint discomfort, or headache.
Consult your doctor if any side effects persist or become severe.
Globus Labs brings you WHO-GMP–certified, high-quality Febuxostat 40 mg sourced from reputed pharmaceutical manufacturers. Uxobus-40 is formulated to deliver safe, potent, and clinically trusted support.
Whether you’re seeking a franchise opportunity, exploring wholesale distribution, or evaluating Globus Labs for international trade, we’re here to help you build a strong, profitable partnership. Let’s discuss how we can grow together and create meaningful value for your business.